Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Doxycycline Crossover Trial for Hereditary Hemorrhagic Telangiectasia

NCT03397004 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT03397004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03397004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Doxycycline Crossover Trial for Hereditary Hemorrhagic Telangiectasia
Lead sponsor
Unity Health Toronto
Phase
Phase 2
Overall status
Completed
Start date
September 12, 2018
Completion date
March 1, 2021
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia (hht)